Citations

Clear

7551 citation(s) found for "Ho, Matthew".

Testing for Herpes Simplex Virus in Low-Volume Cerebrospinal Fluid Samples: Comparison of Three Protocols To Optimize Detection
Espy, Mark J., Irish, Cole L., Binnicker, Matthew J.

Mayo Clinic

Journal of Clinical Microbiology | September 24, 2015 | Volume: 53 | Issue: 12 | Pages: 3897-3899

10.1128/jcm.02386-15 | PMID 26400783 Get It

ABSTRACT Detection of herpes simplex virus 1 and 2 (HSV-1 and HSV-2) in cerebrospinal fluid (CSF) is a medical emergency and requires rapid, sensitive testing. However, the volume of CSF received for microbiological studies may be limited, especially from young children. In this study, we compared three testing protocols to our routine real-time PCR method to determine the most sensitive approach for detecting HSV-1 and HSV-2 in low-volume (≤100 μl) CSF.
The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer
Sahu, Anirban, Iyer, Matthew K. , Malik, Rohit , Chandler, Benjamin C. , Asangani, Irfan A. , Poliakov, Anton , Vergara, Ismael A. , Alshalalfa, Mohammed , Jenkins, Robert B. , Feng, Felix Y. , Prensner, John R. , Davicioni, Elai , Chinnaiyan, Arul

Mayo Clinic

Oncotarget | September 16, 2015 | Volume: 5 | Issue: 6 | Pages: 1434-1438

10.18632/oncotarget.1846 | PMID 24727738 Get It

Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma
Demosthenous, Christos , Stenson, Mary, Wellik, Linda, Link, Brian K. , Hege, Kristen , Sotomayor, Eduardo M. , Han, Jing-Jing, Stenson, Mary J, Wellik, Linda E, Han, Jing , Maurer, Matthew J. , Doǧan, Ahmet , Witzig, Thomas E. , Gupta, Mamta , Link, Brian K

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 11 | Pages: 9488-9501

10.18632/oncotarget.3378 | PMID 25839159 Get It

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer
Zhang, Yaqin , Mehta, Amit, Boufraqech, Myriem , Tian, Ze , Yu, Zhiya , Boxer, Matthew B., Kiefer, Jeffrey , Copland, John A. , Smallridge, Robert C., Li, Zhuyin, Kebebew, Electron , Zhang, Lisa M. , Davis, Sean , Wang, Jing , Shen, Min

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 11 | Pages: 9073-9085

10.18632/oncotarget.3268 | PMID 25940539 Get It

Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression
Polo, María Laura, Riggio, Marina, May, María , Rodriguez, María Jimena , Perrone, María Cecilia , Stallings‐Mann, Melody , Kaen, Diego, Frost, Marlene H., Lanari, Claudia , Frost, Marlene, Boughey, Judy, Radisky, Derek, Polo, María L. , Goetz, Matthew P. , Boughey, Judy C. , Radisky, Derek C. , Novaro, Virginia , Lanari, Claudia

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 26 | Pages: 22081-22097

10.18632/oncotarget.4203 | PMID 26098779 Get It

Cancer caregiver quality of life: need for targeted intervention
Atherton, Pamela J., Kung, Simon , Sloan, Jeff A. , Shahi, Varun, Clark, Matthew M. , Rummans, Teresa A. , Atherton, Philip J. , Lapid, Maria I. , Atherton, Pamela J., Atherton, Philip J.

Mayo Clinic

Psycho-Oncology | September 11, 2015 | Volume: 25 | Issue: 12 | Pages: 1400-1407

10.1002/pon.3960 | PMID 26360934 Get It

AbstractObjectivesCaregiving can negatively impact well‐being. Cancer caregivers face unique challenges given the intense nature of cancer and treatment, which increases their risk for burden, poor quality of life (QOL), and burnout. Studies to reduce caregiver burden demonstrate QOL improvement and distress reduction in the short term. However, few studies exist to address long‐term benefits. We assessed changes in various QOL domains after participation in a QOL intervention for caregivers of patients having newly diagnosed advanced cancer.MethodsOur institutional review board‐approved study randomized patient–caregiver dyads to either usual care or an in‐person group intervention composed of six 90‐min sessions of structured multidisciplinary QOL components delivered over 4 weeks, with 10 follow‐up phone calls within 20 weeks. Caregivers attended four of the six sessions attended by patients. Sessions included physical therapy, coping and communication strategies, mental health education, spirituality, and social needs. Caregiver QOL (Caregiver Quality of Life Index‐Cancer Scale [CQOLC] and Linear Analogue Self‐Assessment [LASA]) and mood (Profile of Mood States‐Brief [POMS‐B]) were measured at baseline and 4, 27, and 52 weeks. Wilcoxon tests and effect sizes were used to compare the caregiver groups.ResultsOf the 131 caregivers (65 intervention and 66 usual care), 116 completed the study. Caregivers post‐intervention (at 4 weeks) had improved scores on LASA Spiritual Well‐being; POMS‐B total score, Vigor/Activity, and Fatigue/Inertia; and CQOLC Adaptation. At long term (at 27 weeks), caregivers retained improvement in POMS‐B Fatigue/Inertia and gained improvements in CQOLC Disruptiveness and Financial Concerns.ConclusionsCaregivers who received the intervention had higher QOL ratings for specific QOL domains but not for overall QOL. Although a comprehensive intervention was helpful, more specific, targeted interventions tailored for individual needs are recommended. Copyright © 2015 John Wiley & Sons, Ltd.
Management of Femoral Bone Loss in Revision Total Hip Arthroplasty
Sculco, Peter K. , Lewallen, David G. , Abdel, Matthew P.

Mayo Clinic

HIP International | September 11, 2015 | Volume: 25 | Issue: 4 | Pages: 380-387

10.5301/hipint.5000272 | PMID 26351121 Get It

Femoral bone loss is frequently encountered during revision total hip arthroplasty. The quality and quantity of remaining bone helps determine the best method for reconstruction. Extensively porous-coated cylindrical stems or titanium fluted tapered devices that achieve fixation in the diaphysis have both demonstrated excellent long-term survivorship. Titanium fluted tapered stems with a modular proximal body allow for more accurate leg length, offset, and version adjustments independent of the distal stem which may optimise hip biomechanics. Intraoperative fractures are more common with cylindrical stems and subsidence with tapered stems, particularly monoblock designs and in both dislocation continues to be one of the most common postoperative complications. In salvage situations in which an ectatic femoral canal is unable to support an uncemented device, impaction bone grafting, allograft-prosthetic composite, or a segmental proximal femoral replacement may be required.
The Metastatic Spine Disease Multidisciplinary Working Group Algorithms
Robinson, Clifford G. , Meyer, Jeffrey , Gangi, Afshin , Callstrom, Matthew R. , Chao, Samuel T. , Tine, Brian Andrew Van, Bruel, Brian M., Long, Jeremiah R. , Timmerman, Robert , Buchowski, Jacob M. , Jennings, Jack W. , Wallace, Adam N, Tran, Nam D, Van Tine, Brian A, Long, Jeremiah, Timmerman, Robert D, Wallace, Adam N. , Tran, Nam , Morris, Jonathan M. , Robinson, Clifford

Mayo Clinic

The Oncologist | September 10, 2015 | Volume: 20 | Issue: 10 | Pages: 1205-1215

10.1634/theoncologist.2015-0085 | PMID 26354526 Get It

AbstractThe Metastatic Spine Disease Multidisciplinary Working Group consists of medical and radiation oncologists, surgeons, and interventional radiologists from multiple comprehensive cancer centers who have developed evidence- and expert opinion-based algorithms for managing metastatic spine disease. The purpose of these algorithms is to facilitate interdisciplinary referrals by providing physicians with straightforward recommendations regarding the use of available treatment options, including emerging modalities such as stereotactic body radiation therapy and percutaneous tumor ablation. This consensus document details the evidence supporting the Working Group algorithms and includes illustrative cases to demonstrate how the algorithms may be applied.Implications for Practice:The Metastatic Spine Disease Multidisciplinary Working Group algorithms can facilitate interdisciplinary referrals by providing physicians with straightforward recommendations regarding available treatment options, including emerging modalities such as stereotactic body radiation therapy and percutaneous tumor ablation.
Procedural Headache Medicine in Neurology Residency Training: A Survey of US Program Directors
Robertson, Carrie E. , Levin, Morris , Friedman, Deborah I. , Robbins, Matthew S. , Ailani, Jessica , Dodick, David W. , Robertson, Carrie E , Friedman, Deborah I

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 9, 2015 | Volume: 56 | Issue: 1 | Pages: 79-85

10.1111/head.12695 | PMID 26352267 Get It

Objective To survey neurology residency program directors (PDs) on trainee exposure, supervision, and credentialing in procedures widely utilized in headache medicine. Background Clinic‐based procedures have assumed a prominent role in headache therapy. Headache fellows obtain procedural competence, but reliance on fellowship‐trained neurologists cannot match the population eligible for treatments. The inclusion of educational modules and mechanisms for credentialing trainees pursuing procedural competence in residency curricula at individual programs is not known. Methods A web‐based survey of US neurology residency PDs was designed by the American Headache Society (AHS) procedural special interest section in collaboration with AHS and American Academy of Neurology's Headache and Facial Pain section leadership. The survey addressed exposure, training, and credentialing in: (1) onabotulinumtoxinA (onabotA) injections, (2) extracranial peripheral nerve blocks (PNBs), and (3) trigger point injections (TPIs). Results Fifty‐five PDs (42.6%) completed the survey. Compared to noncompleters, survey completers were more likely to feature headache fellowships at their institutions (38.2% vs 10.8%, P =0.0002). High exposure (onabotA=90.9%, PNBs=80.0%, TPIs=70.9%) usually featured hands‐on patient instruction (66.2%) and lectures (55.7%). Supervised performance rates were high (onabotA=65.5%, PNBs=60.0%, TPIs=52.7%), usually in continuity clinic (60.0%) or headache elective (50.9%). Headache specialists (69.1%) or general neurology (32.7%) faculty most commonly trained residents. Formal credentialing was uncommon (16.4‐18.2%), mostly by documenting supervised procedures (25.5%). Only 27.3% of programs permitted trainees to perform procedures independently. Most PDs felt procedural exposure (80.0‐90.9%) and competence (50.9‐56.4%) by all trainees was important. Conclusions Resident exposure to procedures for headache is high, but credentialing mechanisms, while desired by most PDs, are not generally in place. Implementation of a credentialing process may ensure trainees enter practice with the ability to perform procedures safely and effectively.
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Adler, Robert A. , Fuleihan, Ghada El‐Hajj , Bauer, Douglas C. , Camacho, Pauline M., Clines, Gregory A. , Edwards, Beatrice J. , Favus, Murray J., Greenspan, Susan L., McKinney, Ross E. , Pignolo, Robert J. , Sellmeyer, Deborah E. , Clarke, Bart L, Drake, Matthew T. , Clarke, B.L. , Compston, Juliet , Bauer, Douglas C , El-Hajj Fuleihan, Ghada

Mayo Clinic

Journal of Bone and Mineral Research | September 9, 2015 | Volume: 31 | Issue: 1 | Pages: 16-35

10.1002/jbmr.2708 | PMID 26350171 Get It

ABSTRACT Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This ASBMR report provides guidance on BP therapy duration with a risk-benefit perspective. Two trials provided evidence for long-term BP use. In the Fracture Intervention Trial Long-term Extension (FLEX), postmenopausal women receiving alendronate for 10 years had fewer clinical vertebral fractures than those switched to placebo after 5 years. In the HORIZON extension, women who received 6 annual infusions of zoledronic acid had fewer morphometric vertebral fractures compared with those switched to placebo after 3 years. Low hip T-score, between –2 and –2.5 in FLEX and below –2.5 in HORIZON extension, predicted a beneficial response to continued therapy. Hence, the Task Force suggests that after 5 years of oral BP or 3 years of intravenous BP, reassessment of risk should be considered. In women at high risk, for example, older women, those with a low hip T-score or high fracture risk score, those with previous major osteoporotic fracture, or who fracture on therapy, continuation of treatment for up to 10 years (oral) or 6 years (intravenous), with periodic evaluation, should be considered. The risk of atypical femoral fracture, but not osteonecrosis of the jaw, clearly increases with BP therapy duration, but such rare events are outweighed by vertebral fracture risk reduction in high-risk patients. For women not at high fracture risk after 3 to 5 years of BP treatment, a drug holiday of 2 to 3 years can be considered. The suggested approach for long-term BP use is based on limited evidence, only for vertebral fracture reduction, in mostly white postmenopausal women, and does not replace the need for clinical judgment. It may be applicable to men and patients with glucocorticoid-induced osteoporosis, with some adaptations. It is unlikely that future trials will provide data for formulating definitive recommendations. © 2015 American Society for Bone and Mineral Research.